CompletedPhase 2

Efficacity and Safety of Metformin XR in CKD Stage 1 to 3

France12 participantsStarted 2017-08-30

Plain-language summary

There is limited data availability on effect of Metformin XR on 24-h plasma glucose, and there is no available data in chronic kidney disease (CKD). The planned study aims to provide data on glucose plasma level in relation to metformin plasma level in Diabetes Type II patients.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Type 2 diabetes patients aged between 18 and 80 years requiring metformin (and any other antidiabetic treatment) Exclusion Criteria: * Pregnancy and lactation * Hyperlactatemia (\> 2.5 mmol/L) * No creatinine levels available since 3 months * Severe hepatic insufficiency * No liver function parameters available * Need of investigation with iodized contrast media * Hypersensitivity to metformin

What they're measuring

Efficacy of once daily Metformin XR on 24-h blood glucose control

Timeframe: week 12

Trial details

NCT IDNCT02895750

SponsorCentre Hospitalier Universitaire, Amiens

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-01-08

View on ClinicalTrials.gov More Renal Insufficiency, Chronic trials